Merck & Co needs to undertake a "major restructuring" in the wake of lacklustre sales and recent R&D setbacks, according to analysts at Leerink Swann.
Seamus Fernandez and Ario Arabi write in a research report that pressure is building on Merck's management to improve R&D productivity, maintain operating margins and return cash to investors, and signs of a shake-up of the business would be "well received".
http://www.pharmatimes.com/Article/13-08-21/Merck_needs_to_cut_costs_says_analyst.aspx?
Seamus Fernandez and Ario Arabi write in a research report that pressure is building on Merck's management to improve R&D productivity, maintain operating margins and return cash to investors, and signs of a shake-up of the business would be "well received".
http://www.pharmatimes.com/Article/13-08-21/Merck_needs_to_cut_costs_says_analyst.aspx?
No comments:
Post a Comment